Erik Harris's most recent trade in Rezolute Inc was a trade of 60,000 Director Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 25, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Rezolute Inc | Erik Harris | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2025 | 60,000 | 60,000 | - | - | Director Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 30,246 | 30,246 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 18,443 | 102,419 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 16,813 | 83,976 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 42.10 per share. | 01 Mar 2025 | 15,103 | 87,855 (0%) | 0% | 42.1 | 635,836 | Common Stock |
| Denali Therapeutics Inc | Erik Harris | Director | 31 May 2024 | 17,901 | 17,901 | - | - | Stock Option (right to buy) | ||
| Denali Therapeutics Inc | Erik Harris | Director | 31 May 2024 | 5,967 | 17,052 (0%) | 0% | 0 | Common Stock | ||
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 34,200 | 34,200 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 19,400 | 70,681 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 53.76 per share. | 01 Mar 2024 | 4,768 | 67,163 (0%) | 0% | 53.8 | 256,328 | Common Stock |
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 957 | 71,638 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 48.20 per share. | 19 Jun 2023 | 305 | 57,281 (0%) | 0% | 48.2 | 14,701 | Common Stock |
| Denali Therapeutics Inc | Erik Harris | Director | 01 Jun 2023 | 12,649 | 12,649 | - | - | Stock Option (right to buy) | ||
| Denali Therapeutics Inc | Erik Harris | Director | 01 Jun 2023 | 4,216 | 11,085 (0%) | 0% | 0 | Common Stock | ||
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 39,400 | 39,400 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 22,000 | 60,823 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 45.25 per share. | 01 Mar 2023 | 3,664 | 57,344 (0%) | 0% | 45.3 | 165,796 | Common Stock |
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 2,663 | 38,823 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 54.78 per share. | 19 Jun 2022 | 295 | 36,160 (0%) | 0% | 54.8 | 16,160 | Common Stock |
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 24,900 | 24,900 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 14,000 | 36,317 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 66.62 per share. | 01 Mar 2022 | 2,713 | 22,317 (0%) | 0% | 66.6 | 180,740 | Common Stock |
| Denali Therapeutics Inc | Erik Harris | Director | 03 Feb 2022 | 20,607 | 20,607 | - | - | Stock Option (right to buy) | ||
| Denali Therapeutics Inc | Erik Harris | Director | 03 Feb 2022 | 6,869 | 6,869 (0%) | 0% | 0 | Common Stock | ||
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 81.14 per share. | 14 Oct 2021 | 303 | 25,030 (0%) | 0% | 81.1 | 24,585 | Common Stock |
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 91.53 per share. | 06 Jul 2021 | 375 | 25,333 (0%) | 0% | 91.5 | 34,324 | Common Stock |
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 94.96 per share. | 19 Jun 2021 | 572 | 25,708 (0%) | 0% | 95.0 | 54,317 | Common Stock |
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 94.63 per share. | 19 Jun 2021 | 437 | 26,280 (0%) | 0% | 94.6 | 41,353 | Common Stock |
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 113.67 per share. | 06 May 2021 | 393 | 26,717 (0%) | 0% | 113.7 | 44,672 | Common Stock |
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 113.68 per share. | 06 May 2021 | 307 | 27,110 (0%) | 0% | 113.7 | 34,900 | Common Stock |
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 104.28 per share. | 20 Apr 2021 | 396 | 27,417 (0%) | 0% | 104.3 | 41,295 | Common Stock |
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 11,000 | 11,000 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 5,500 | 26,354 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 4,636 | 30,990 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 138.17 per share. | 01 Mar 2021 | 2,470 | 28,520 (0%) | 0% | 138.2 | 341,280 | Common Stock |
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 138.16 per share. | 01 Mar 2021 | 707 | 27,813 (0%) | 0% | 138.2 | 97,679 | Common Stock |
| Ultragenyx Pharmaceutical ... | Erik Harris | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 88.00 per share. | 14 Oct 2020 | 220 | 23,370 (0%) | 0% | 88 | 19,360 | Common Stock |